For Desloratadine and its preparations marketed for paediatric use (under 12 years of age), what is the schedule classification?

Desloratadine, an antihistamine commonly used to relieve allergy symptoms, is classified as a Schedule 3 drug for its preparations marketed for paediatric use, specifically for those under 12 years of age. This classification allows the drug to be sold over the counter but with some regulation in pharmacies, as it may require the pharmacist’s intervention for safe dispensing, which is particularly important in paediatric populations where dosing and safety need to be carefully considered.

Schedule 3 drugs are available without a prescription, but they are still subject to some restrictions, ensuring that they are used safely and appropriately. In the context of paediatric patients, the schedule classification acknowledges that while Desloratadine is considered safe and effective for treating allergies in children, dispensing practices still need to be monitored by pharmacy professionals to avoid misuse and ensure proper use.

This contrasts with other classifications like Schedule 2, which requires a pharmacist’s intervention for sale but generally involves more restricted medications. Unscheduled substances can be found on store shelves without any pharmacy involvement, while Schedule 4 includes prescription medications that require careful monitoring and cannot be sold without a prescription. Thus, the Schedule 3 classification effectively balances accessibility and safety for Desloratadine when used in paediatric care.